Who owns KINNATE BIOPHARMA INC?
- Ticker: KNTE
- CUSIP Number: 49705r105
Tip: Access positions for across all investors
Analyze quarterly positions in Kinnate Biopharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Kinnate Biopharma stock
Who bought or sold KINNATE BIOPHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| OrbiMed Advisors | 8.0M | $19M | 0% | Dec 2023 |
|
| Tang Capital Management | 2.6M | $6.2M | 100% | Dec 2023 |
|
| Lynx1 Capital Management | 2.0M | $4.7M | 0% | Dec 2023 |
|
| Viking Global Investors | 1.8M | $4.3M | 0% | Dec 2023 |
|
| Vanguard Group | 1.0M | $2.5M | 5% | Dec 2023 |
|
| Deltec Asset Management | 1.0M | $2.8M | 100% | Mar 2024 |
|
| Millennium Management | 565k | $1.3M | 1% | Dec 2023 |
|
| BML Capital Management | 468k | $1.1M | 100% | Dec 2023 |
|
| Citadel Advisors | 433k | $1.0M | -59% | Dec 2023 |
|
| GSA Capital Partners | 339k | $803k | -9% | Dec 2023 |
|
| Two Sigma Investments | 300k | $710k | 118% | Dec 2023 |
|
| Acuitas Investments | 290k | $687k | 100% | Dec 2023 |
|
| Marshall Wace | 195k | $461k | 131% | Dec 2023 |
|
| Goldman Sachs Group | 156k | $370k | 98% | Dec 2023 |
|
| Two Sigma Advisers | 153k | $363k | 43% | Dec 2023 |
|
| D. E. Shaw & Co | 151k | $357k | 170% | Dec 2023 |
|
| Deutsche Bank Aktiengesellschaft | 115k | $272k | 0% | Dec 2023 |
|
| Exome Asset Management | 84k | $199k | 100% | Dec 2023 |
|
| Jane Street | 77k | $183k | 215% | Dec 2023 |
|
| Connor, Clark & Lunn Investment Management | 77k | $182k | 47% | Dec 2023 |
|
| Occudo Quantitative Strategies | 70k | $166k | 100% | Dec 2023 |
|
| Marquette Asset Management | 60k | $142k | 100% | Dec 2023 |
|
| Squarepoint Ops | 59k | $139k | -23% | Dec 2023 |
|
| DAFNA Capital Management | 50k | $119k | -52% | Dec 2023 |
|
| Simplex Trading | 44k | $105k | 100% | Dec 2023 |
|
| Two Sigma Securities | 31k | $74k | 100% | Dec 2023 |
|
| Dimensional Fund Advisors | 15k | $35k | 19% | Dec 2023 |
|
| Barclays | 15k | $35k | 0% | Dec 2023 |
|
| Dynamic Technology Lab Private | 14k | $33k | 100% | Dec 2023 |
|
| Cubist Systematic Strategies | 13k | $30k | -71% | Dec 2023 |
|
| Bank of America Corporation | 5.8k | $14k | -28% | Dec 2023 |
|
| UBS Group | 5.1k | $12k | 100% | Dec 2023 |
|
| Rhumbline Advisers | 2.9k | $7.0k | 0% | Dec 2023 |
|
| Point72 Asia | 2.2k | $5.2k | 100% | Dec 2023 |
|
| Federated Investors | 585.00 | $1.4k | -66% | Dec 2023 |
|
| Wells Fargo & Company | 141.00 | $334.000800 | 5% | Dec 2023 |
|
| Pacific Capital Wealth Advisors | 100.00 | $237.000000 | 100% | Dec 2023 |
|
| Jpmorgan Chase & Co | 63.00 | $149.001300 | -99% | Dec 2023 |
|
| Royal Bank of Canada | 3.00 | $0 | -88% | Dec 2023 |
|
Who sold out of Kinnate Biopharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Nextech Invest | Sep 2023 | 2.3M | $3.3M |
| Vida Ventures Advisors | Dec 2023 | 2.2M | $5.2M |
| Jacobs Levy Equity Management | Sep 2023 | 450k | $629k |
| Citigroup | Sep 2023 | 421k | $589k |
| Man Group | Sep 2023 | 98k | $137k |
| Sargent Investment Group | Sep 2023 | 12k | $17k |
| China Universal Asset Management | Sep 2023 | 1.2k | $2.0k |
| Daiwa Securities Group | Sep 2023 | 127.00 | $0 |